Biocin

Chlorpheniramine Maleate

COMPOSITION

Biocin 4 mg Tablet: Each tablet contains 4 milligrams of chlorphenamine maleate
Biocin 100 ml Syrup : Each 5 ml syrup contains Chlorpheniramine Maleate BP 2 mg.

THERAPEUTIC INDICATIONS

Biocin tablets are indicated for symptomatic control of all allergic conditions responsive to antihistamines, including hay fever, vasomotor rhinitis, urticaria, angioneurotic oedema, food allergy, drug and serum reactions, insect bites.
Also indicated for the symptomatic relief of itch associated with chickenpox.

DOSAGE AND ADMINISTRATION

Oral Administration only
Do no exceed the stated dose or frequency of dosing
Adults and children 12 years and over: 1 tablet 4 to 6 hourly. Maximum daily dose: 6 tablets (24 mg) in any 24 hours
Elderly: The elderly are more likely to experience neurological anticholinergic effects. Consideration should be given to using a lower daily dose (e.g. a maximum of 12 mg in any 24 hours).
Children aged 6 - 12 years: ½ tablet 4 to 6 hourly. Maximum daily dose: 3 tablets (12mg) in any 24 hours.
Upto 1 Year : ½ Teaspoonful 2 times daily
1-5 years: ½-1 Teaspoonful 2 times daily

CONTRAINDICATIONS

Biocin tablets are contra-indicated in patients who are hypersensitive to antihistamines or to any of the tablet ingredients.
The anticholinergic properties of chlorphenamine are intensified by monoamine oxidase inhibitors (MAOIs). Biocin Tablets is therefore contra-indicated in patients who have been treated with MAOIs within the last fourteen days.

PREGNANCY AND LACTATION

Pregnancy: There are no adequate data from the use of chlorphenamine maleate in pregnant women. The potentisl risk for humans is unknown. Use during the third trimester may result in reactions in the newborn or premature neonates. Not to be used during pregnancy unless considered essentially by a physician.
Lactation: Chlorphenamine maleate and other antihistamine may inhibit lactation and may be secreted in breast milk. Not to be used during lactation unless considered essential by a physician

SIDE EFFECT

Specific estimation of the frequency of adverse events for OTC products is inherently difficult (particularly numerator data). Adverse reactions which have been observed in clinical trails and which are considered to be common (occurring in?1% to <10% of subjects) or very common (occurring in ?10% of subjects) are listed below by MedDRA Sytem Organ Class. The frequency of other adverse reactions identified during post-marketing use is unknown.

OVERDOSE

The estimated lethal dose of chlorphenamine is 25 to 50mg/kg body weight. Symptoms and signs include sedation, paradoxical excitation of the CNS, toxic psychosis, convulsions, apnoea, anticholinergic effects, dystonic reactions and cardiovascular collapse including arrhythmias.

Manufactured by
BIOPHARMA LIMITED
A-116, BSCIC Industrial Estate
Tongi, Gazipur, Bangladesh

For further query on the use of this medicine, consult to a registered Doctor or Pharmacist.